{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:05:26Z","timestamp":1759104326420,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00c3\u00a7\u00c3\u00a3o para a Ci\u00c3\u00aancia e a Tecnologia","doi-asserted-by":"publisher","award":["VIH\/SAU\/0029\/2011"],"award-info":[{"award-number":["VIH\/SAU\/0029\/2011"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007395","name":"Instituto Nacional de Ci\u00c3\u00aancia e Tecnologia para Excitotoxicidade e Neuroprote\u00c3\u00a7\u00c3\u00a3o","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SFRH\/BPD\/76225\/2011"],"award-info":[{"award-number":["SFRH\/BPD\/76225\/2011"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.antiviral.2018.10.018","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T11:10:35Z","timestamp":1541157035000},"page":"85-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["In\u00a0vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2"],"prefix":"10.1016","volume":"161","author":[{"given":"In\u00eas","family":"B\u00e1rtolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Borrego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-8255","authenticated-orcid":false,"given":"Perp\u00e9tua","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umbelina","family":"Caixas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas V.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Taveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.10.018_bib1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.RA117.000177","article-title":"Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway","volume":"293","author":"Alvarez","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.10.018_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3851\/IMP1996","article-title":"Baseline susceptibility of primary HIV-2 to entry inhibitors","volume":"17","author":"Borrego","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.10.018_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/088922203322230905","article-title":"Pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy","volume":"19","author":"Brandin","year":"2003","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2018.10.018_bib4","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1128\/AAC.01152-15","article-title":"In\u00a0vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate","volume":"59","author":"Callebaut","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1468-1293.2011.00963.x","article-title":"Population mobility and the changing epidemics of HIV-2 in Portugal","volume":"13","author":"Carvalho","year":"2012","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2018.10.018_bib6","first-page":"152","article-title":"New HIV and AIDS diagnoses, France, 2003-2013","volume":"9\u201310","author":"Cazein","year":"2015","journal-title":"Bull Epidemiol Hebd."},{"key":"10.1016\/j.antiviral.2018.10.018_bib7","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/cid\/cit104","article-title":"HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe","volume":"56","author":"Charpentier","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.10.018_bib8","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1128\/JCM.02389-10","article-title":"An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study","volume":"49","author":"Damond","year":"2011","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.10.018_bib9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/135965350501000702","article-title":"Letter. In\u00a0vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene","volume":"10","author":"Damond","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.10.018_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/135965350400900422","article-title":"Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen","volume":"9","author":"Damond","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.10.018_bib11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.tim.2008.09.003","article-title":"HIV-2: the forgotten AIDS virus","volume":"16","author":"de Silva","year":"2008","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2018.10.018_bib12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJM200102153440702","article-title":"Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia","volume":"344","author":"Deeks","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.10.018_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jmv.20174","article-title":"High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen","volume":"74","author":"Descamps","year":"2004","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.antiviral.2018.10.018_bib14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/JVI.02259-14","article-title":"Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses","volume":"89","author":"Deuzing","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2018.10.018_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12977-016-0320-7","article-title":"A\u00a0genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support","volume":"13","author":"Doring","year":"2016","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2018.10.018_bib16","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/AAC.48.5.1640-1646.2004","article-title":"Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity","volume":"48","author":"Dutschman","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib17","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/QAD.0b013e32830edd44","article-title":"A\u00a0call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa","volume":"22","author":"Gottlieb","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2018.10.018_bib18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1086\/339295","article-title":"Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa","volume":"185","author":"Gottlieb","year":"2002","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.10.018_bib19","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(15)00231-3","article-title":"Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial","volume":"3","author":"Gupta","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2018.10.018_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/aid.2008.0259","article-title":"Molecular epidemiology of HIV type 2 infections in South India","volume":"25","author":"Gurjar","year":"2009","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2018.10.018_bib21","first-page":"335","article-title":"Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2-infected women in a community-based cohort in the Gambia","volume":"38","author":"Hansmann","year":"2005","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.10.018_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3851\/IMP2628","article-title":"Recent findings on the mechanisms involved in tenofovir resistance","volume":"23","author":"Iyidogan","year":"2014","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib23","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib24","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1128\/AAC.01195-13","article-title":"In\u00a0vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations","volume":"57","author":"Li","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3851\/IMP3125","article-title":"Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide or elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate","volume":"22","author":"Margot","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.10.018_bib26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/15284336.2016.1142731","article-title":"Rare emergence of drug resistance in HIV-1 treatment-naive patients after 48 weeks of treatment with elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","volume":"17","author":"Margot","year":"2016","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.antiviral.2018.10.018_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2016.05.012","article-title":"High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate","volume":"132","author":"Margot","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.018_bib28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1468-1293.2006.00404.x","article-title":"Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in study 903","volume":"7","author":"Margot","year":"2006","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2018.10.018_bib29","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/00126334-200411010-00002","article-title":"Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate","volume":"37","author":"McColl","year":"2004","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.10.018_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2013.12.001","article-title":"Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection","volume":"102","author":"Menendez-Arias","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.018_bib31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","author":"Miller","year":"2004","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.10.018_bib32","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1128\/AAC.49.8.3355-3360.2005","article-title":"Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in\u00a0vitro","volume":"49","author":"Nitanda","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1128\/AAC.00870-06","article-title":"Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors","volume":"51","author":"Ntemgwa","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib34","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1128\/AAC.00154-09","article-title":"Antiretroviral drug resistance in human immunodeficiency virus type 2","volume":"53","author":"Ntemgwa","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014638","article-title":"Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity","volume":"6","author":"Paquet","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.10.018_bib36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.10.018_bib37","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.10.018_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2018.10.018_bib39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/AAC.01004-07","article-title":"Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in\u00a0vitro","volume":"52","author":"Smith","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib40","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1128\/AAC.01326-15","article-title":"The nucleoside analog BMS-986001 shows greater in\u00a0vitro activity against HIV-2 than against HIV-1","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.018_bib41","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1128\/JVI.01921-10","article-title":"Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients","volume":"85","author":"Soares","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2018.10.018_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.meegid.2016.08.010","article-title":"Hiv-2 molecular epidemiology","volume":"46","author":"Visseaux","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.antiviral.2018.10.018_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","article-title":"Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis","volume":"9","author":"Witvrouw","year":"2004","journal-title":"Antivir. Ther."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:16Z","timestamp":1759062436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218305424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":43,"alternative-id":["S0166354218305424"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.018","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}